Ravulizumab for treating paroxysmal nocturnal haemoglobinuria – guidance (TA698)

NICE recommend ravulizumab as an option for treating paroxysmal nocturnal haemoglobinuria in adults with haemolysis with clinical symptoms suggesting high disease activity, or whose disease is clinically stable after having eculizumab for at least 6 months.

National Institute for Health and Care Excellence